Tongmai Jiangtang
Abdominal Obesity-Metabolic Syndrome
Explore 42 assets in Abdominal Obesity-Metabolic Syndrome →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Guangdong Provincial Hospital of Traditional Chinese Medicine
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06908473CT.gov Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Abdominal Obesity-Metabolic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tongmai Jiangtang (this asset) | Guangdong Provincial Hospital of Traditional Chinese Medicine | P3 | CCC · 54 |
| Topiramate | All India Institute of Medical Sciences, Bhubaneswar | P4 | BBB |
| Atorvastatin | Seoul National University Hospital | P4 | BBB |
| Pioglitazone | Philip Kern | P4 | BBB |
| Simvastatin | Jaime Daniel Mondragon | P4 | BBB |
| Rosuvastatin | Hamdard University | P4 | BBB |
| Olmesartan Medoxomil | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | P4 | BBB |
| Amlodipine | Italo Biaggioni | P4 | BB |
| Ezetimibe | Samsung Medical Center | P4 | BB |
+42 more in the Abdominal Obesity-Metabolic Syndrome cohort
Other indications for Tongmai Jiangtang
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cerebrovascular Disorder | — | P3 | B · 60 |
| Chronic Kidney Disease | — | P3 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tongmai Jiangtang in Abdominal Obesity-Metabolic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tongmai-jiangtang-abdominal-obesity-metabolic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →